Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neurocrine Biosciences (NBIX) Interest Expenses (2017 - 2024)

Neurocrine Biosciences (NBIX) has disclosed Interest Expenses for 7 consecutive years, with $1.1 million as the latest value for Q1 2024.

  • For the quarter ending Q1 2024, Interest Expenses changed 0.0% year-over-year to $1.1 million, compared with a TTM value of $1.1 million through Dec 2024, down 50.0%, and an annual FY2019 reading of $32.0 million, up 4.69% over the prior year.
  • Interest Expenses was $1.1 million for Q1 2024 at Neurocrine Biosciences, roughly flat from $1.1 million in the prior quarter.
  • Across five years, Interest Expenses topped out at $8.5 million in Q3 2020 and bottomed at $1.1 million in Q1 2023.
  • Average Interest Expenses over 4 years is $5.3 million, with a median of $6.4 million recorded in 2021.
  • The sharpest move saw Interest Expenses rose 6.25% in 2020, then fell 25.3% in 2021.
  • Year by year, Interest Expenses stood at $8.5 million in 2020, then fell by 22.35% to $6.6 million in 2021, then plummeted by 83.33% to $1.1 million in 2023, then changed by 0.0% to $1.1 million in 2024.
  • Business Quant data shows Interest Expenses for NBIX at $1.1 million in Q1 2024, $1.1 million in Q3 2023, and $1.1 million in Q1 2023.